Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Modeling the Impact of Antimicrobial Resistance on Medical Preparedness and Response for a Nuclear or Radiological Public Health Emergency.
Journal: Disaster medicine and public health preparedness
Published: September 10, 2025
Landscape of Post-Marketing Requirements Under the Pediatric Research Equity Act for Antibiotics from 2009-2024.
Journal: Antibiotics (Basel, Switzerland)
Published: April 29, 2025
US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 16, 2024
FDA, CDC, and NIH Co-sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 16, 2024
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Journal: Antimicrobial agents and chemotherapy
Published: November 14, 2022
Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial.
Journal: JAC-antimicrobial resistance
Published: March 10, 2021
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: April 24, 2020
Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
Journal: Antimicrobial agents and chemotherapy
Published: September 25, 2019
A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
Journal: Open forum infectious diseases
Published: September 16, 2019
Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study.
Journal: Sexually transmitted diseases
Published: April 16, 2019
Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 09, 2019
Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin.
Journal: Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
Published: May 04, 2018
Last Updated: 09/26/2026